EP1141339A4 - Recepteur humain du facteur de croissance des fibroblastes utilise comme co-recepteur dans l'injection du virus 2 associe aux adenovirus - Google Patents

Recepteur humain du facteur de croissance des fibroblastes utilise comme co-recepteur dans l'injection du virus 2 associe aux adenovirus

Info

Publication number
EP1141339A4
EP1141339A4 EP99968572A EP99968572A EP1141339A4 EP 1141339 A4 EP1141339 A4 EP 1141339A4 EP 99968572 A EP99968572 A EP 99968572A EP 99968572 A EP99968572 A EP 99968572A EP 1141339 A4 EP1141339 A4 EP 1141339A4
Authority
EP
European Patent Office
Prior art keywords
receptor
adeno
infection
growth factor
fibroblast growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99968572A
Other languages
German (de)
English (en)
Other versions
EP1141339A1 (fr
Inventor
Arun Srivastava
Keyun Qing
Cathryn Mah
Jonathan Hansen
Shangzhen Zhou
Varavani Dwarki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of EP1141339A1 publication Critical patent/EP1141339A1/fr
Publication of EP1141339A4 publication Critical patent/EP1141339A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
EP99968572A 1998-12-31 1999-12-29 Recepteur humain du facteur de croissance des fibroblastes utilise comme co-recepteur dans l'injection du virus 2 associe aux adenovirus Withdrawn EP1141339A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11459698P 1998-12-31 1998-12-31
US114596P 1998-12-31
PCT/US1999/031220 WO2000039311A1 (fr) 1998-12-31 1999-12-29 Recepteur humain du facteur de croissance des fibroblastes utilise comme co-recepteur dans l'injection du virus 2 associe aux adenovirus

Publications (2)

Publication Number Publication Date
EP1141339A1 EP1141339A1 (fr) 2001-10-10
EP1141339A4 true EP1141339A4 (fr) 2002-04-17

Family

ID=22356219

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99968572A Withdrawn EP1141339A4 (fr) 1998-12-31 1999-12-29 Recepteur humain du facteur de croissance des fibroblastes utilise comme co-recepteur dans l'injection du virus 2 associe aux adenovirus

Country Status (5)

Country Link
EP (1) EP1141339A4 (fr)
JP (1) JP2002533128A (fr)
AU (1) AU2596400A (fr)
CA (1) CA2358094A1 (fr)
WO (1) WO2000039311A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4552700A (en) * 1999-04-19 2000-11-02 Ballermann, Barbara Jutta Gene therapy
DK1469878T3 (da) 2002-01-31 2011-07-18 Max Planck Gesellschaft FGFR agonister
EP1332761A1 (fr) * 2002-01-31 2003-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Agonistes des récepteurs du facteur de croissance des fibroblastes
AU2010223888A1 (en) * 2009-03-13 2011-10-06 Egen, Inc. Compositions and methods for the delivery of biologically active RNAs
US8808684B2 (en) 2010-09-10 2014-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epidermal growth factor receptor (EGFR) and methods of use in adenoviral-associated virus type 6 (AAV6) transduction
CN116688095B (zh) * 2023-03-08 2024-09-10 中国人民解放军海军军医大学 受体酪氨酸激酶fgfr1的抗疱疹病毒作用及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000999A1 (fr) * 1990-07-06 1992-01-23 Rhone-Poulenc Rorer International (Holdings) Inc. Recepteurs de facteur de croissance fibroblastique
WO1994003620A2 (fr) * 1992-07-29 1994-02-17 Chiron Corporation Procede permettant d'accroitre l'expression de proteines virales
WO1995000633A2 (fr) * 1993-06-17 1995-01-05 Children's Medical Center Corporation Construction et utilisation de structures synthetiques codant la syndecane
WO1998011221A2 (fr) * 1996-09-13 1998-03-19 Dana-Farber Cancer Institute Car, un nouveau recepteur du virus de coxsackie et d'adenovirus
WO1999011652A1 (fr) * 1997-09-02 1999-03-11 Advanced Research And Technology Institute Role de la phosphorylation de la tyrosine d'une proteine cellulaire dans l'expression d'un transgene induit par deux genes d'un virus associe a un adenovirus

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000999A1 (fr) * 1990-07-06 1992-01-23 Rhone-Poulenc Rorer International (Holdings) Inc. Recepteurs de facteur de croissance fibroblastique
WO1994003620A2 (fr) * 1992-07-29 1994-02-17 Chiron Corporation Procede permettant d'accroitre l'expression de proteines virales
WO1995000633A2 (fr) * 1993-06-17 1995-01-05 Children's Medical Center Corporation Construction et utilisation de structures synthetiques codant la syndecane
WO1998011221A2 (fr) * 1996-09-13 1998-03-19 Dana-Farber Cancer Institute Car, un nouveau recepteur du virus de coxsackie et d'adenovirus
WO1999011652A1 (fr) * 1997-09-02 1999-03-11 Advanced Research And Technology Institute Role de la phosphorylation de la tyrosine d'une proteine cellulaire dans l'expression d'un transgene induit par deux genes d'un virus associe a un adenovirus

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), 40th Annual Meeting of the American Society of Hematology;Miami Beach, Florida, USA; December 4-8, 1998, pages 150A, ISSN: 0006-4971 *
C. MAH ET AL.,: "Adeno-associated virus type 2-mediated gene transfer : Role of epidermal growth factor receptor protein tyrosine kinase in transgene expression", J VIROLOGY, vol. 72, no. 12, December 1998 (1998-12-01), pages 9835 - 9843, XP002190083 *
C. SUMMERFORD AND RJ SAMULSKI: "Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions", J VIROLOGY, vol. 72, no. 2, February 1998 (1998-02-01), pages 1438 - 1445, XP002190085 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 15 November 1998 (1998-11-15), QING K Y ET AL: "Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2.", XP002190087, Database accession no. PREV199900108041 *
K. QING ET AL.,: "Adeno-associated virus type 2-mediated gene transfer : Correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo", J VIROLOGY, vol. 72, no. 2, February 1998 (1998-02-01), pages 1593 - 1599, XP002190084 *
K. QING ET AL.,: "Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2", NATURE MEDICINE, vol. 5, no. 1, January 1999 (1999-01-01), pages 71 - 77, XP002190086 *
See also references of WO0039311A1 *

Also Published As

Publication number Publication date
CA2358094A1 (fr) 2000-07-06
JP2002533128A (ja) 2002-10-08
EP1141339A1 (fr) 2001-10-10
AU2596400A (en) 2000-07-31
WO2000039311A1 (fr) 2000-07-06

Similar Documents

Publication Publication Date Title
GB2259451B (en) Genital-vulva pad sanitary napkin construction
TW359179U (en) Disposable sanitary mask
CY2005A (en) 3-(2-(dimethylamino)ethyl)-N-methyl-1H-indole-5- methanesulphonamide sulphate (2:1)
NO944067D0 (no) Generelt tynt, böyelig sanitetsbind med stivet midtparti
GB9208125D0 (en) Ophthalmoscopic attachment for a surgical microscope
ZA915563B (en) Recombinant marek's disease virus
EP1141339A4 (fr) Recepteur humain du facteur de croissance des fibroblastes utilise comme co-recepteur dans l'injection du virus 2 associe aux adenovirus
GB9713793D0 (en) Disposable nappy
GB9001466D0 (en) Extracellular form of the human fibroblast growth factor receptor
EP0572505A4 (en) Human platelet-derived growth factor receptors
PL333743A1 (en) Baby's napkin
ZA955761B (en) Marek's disease virus vaccine
MA24411A1 (fr) Muteines de l'obesite
GB8922645D0 (en) A disposable napkin
GB2317800B (en) Angler's weight
FR2771270B1 (fr) Dispositif d'ajustement variable de la souplesse d'un sommier a lattes
GB2327857B (en) A disposable nappy
FI971532A0 (fi) HER4, ihmisen reseptorityrosiinikinaasi, joka kuuluu ryhmään ihokasvutekijäreseptorit
IT1269414B (it) Attacco per protesi dentale rimovibile
GB9816057D0 (en) A sanitary hygiene underarm napkin"vapours"
KR960009980U (ko) 여성용 생리대
GB9408258D0 (en) Hygienic disposable nappy
PL108968U1 (en) Fastener for disposable baby's napkin
BR7100282U (pt) Descanso de nenen
PL57213Y1 (en) Disposable orthopaedic collar

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010719

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020301

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20020507